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Identification of low molecular weight nuclear
complexes containing integrase during the early
stages of HIV-1 infection
Annabelle Gérard1,2,3†, Nicolas Soler1,2,3†, Emmanuel Ségéral1,2,3, Michael Belshan4,5 and Stéphane Emiliani1,2,3*
Abstract
Background: HIV-1 replication requires integration of its reverse transcribed viral cDNA into a host cell
chromosome. The DNA cutting and joining reactions associated to this key step are catalyzed by the viral protein
integrase (IN). In infected cells, IN binds the viral cDNA, together with viral and cellular proteins, to form large
nucleoprotein complexes. However, the dynamics of IN complexes formation is still poorly understood.
Results: Here, we characterized IN complexes during the early stages of T-lymphocyte infection. We found that
following viral entry into the host cell, IN was rapidly targeted to proteasome-mediated degradation. Interactions
between IN and cellular cofactors LEDGF/p75 and TNPO3 were detected as early as 6 h post-infection. Size
exclusion chromatography of infected cell extracts revealed distinct IN complexes in vivo. While at 2 h
post-infection the majority of IN eluted within a high molecular weight complex competent for integration (IN
complex I), IN was also detected in a low molecular weight complex devoid of full-length viral cDNA (IN complex
II, ~440 KDa). At 6 h post-infection the relative proportion of IN complex II increased. Inhibition of reverse
transcription or integration did not alter the elution profile of IN complex II in infected cells. However, in cells
depleted for LEDGF/p75 IN complex II shifted to a lower molecular weight complex (IN complex III, ~150 KDa)
containing multimers of IN. Notably, cell fractionation experiments indicated that both IN complex II and III were
exclusively nuclear. Finally, IN complex II was not detected in cells infected with a virus harboring a mutated IN
defective for LEDGF/p75 interaction and tetramerization.
Conclusions: Our findings indicate that, shortly after viral entry, a significant portion of DNA–free IN that is distinct
from active pre-integration complexes accumulates in the nucleus.
Keywords: Human immunodeficiency virus, Integrase, Pre-integration complex, LEDGF/p75
Background
During the early stages of retroviral replication, the virus
travels from the cellular plasma membrane across the
nuclear pore to finally integrate its viral cDNA into the
host cell genome. These early events first require the re-
verse transcription of the viral RNA into a linear double
strand cDNA copy by the viral reverse transcriptase
(RT). Once synthesized, this cDNA becomes part of a
large nucleoprotein complex, called the pre-integration
complex (PIC) (reviewed in [1]). PICs from Moloney
murine leukemia virus (MLV) [2-4] or Human immuno-
deficiency virus (HIV) [5-7] can be partially purified
after cell infection and can efficiently integrate their
associated reverse transcribed viral cDNA into heterol-
ogous DNA targets in vitro [8]. The integration reaction
is mediated by the retroviral integrase (IN) [9-11].
Within the PIC, IN binds to viral cDNA ends [12-14]
and catalyzes the DNA cutting and joining reactions.
First, the 3 processing reaction consists in the hydroly-
sis of a dinucleotide at each end of the viral cDNA
[4,15,16]. Then, exposed recessed 3 hydroxyl groups of
the viral cDNA are joined to the 5 ends of the cut host
target DNA [4-6,15]. At this stage, cellular enzymes are
probably in charge of removing the 5 unpaired viral
DNA ends and subsequently catalyze the gap filling and
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ligation reactions of host-viral DNA junctions [17].
Human immunodeficiency virus type-1 (HIV-1) inte-
gration produces a 5 bp duplication of the DNA host
sequence at each end of the integrated provirus [18].
Retroviral PICs are large nucleoprotein complexes that
contain several viral and cellular proteins in addition to
IN and viral cDNA. Biochemical studies indicate that
HIV-1 PICs contain the viral nucleocapsid (NC), matrix
(MA), Vpr and RT proteins [19-25]. In contrast with
MLV [2,26], HIV-1 PICs were shown to be devoid of CA
[19-25]. In addition, cellular proteins including barrier
to auto-integration factor (BAF), high mobility group
protein HMGA, Ku and LEDGF/p75 have been found to
associate with partially purified HIV-1 PICs [20,27-29].
HIV and other lentiviruses have the ability to infect
non-dividing cells, such as terminally differentiated
macrophages. Therefore, this large viral nucleoprotein
complex (>50 nm) must pass through the nuclear pore
with the active participation of cellular factors involved
in nucleo-cytoplasmic shuttling. Although several viral
proteins within the HIV-1 PIC contain karyophilic signals
(MA, Vpr and IN), their exact role during PIC transloca-
tion into the nucleus is still controversial [30]. The central
polypurine track (cPPT), a cis-acting sequence that forms
a short triple stranded DNA structure (the central DNA
Flap) during reverse transcription, is also implicated in the
nuclear import of HIV PICs [31,32]. Importantly, reports
show that the HIV-1 capsid (CA) is the dominant viral
determinant for HIV-1 infection of non-dividing cells,
and the kinetic of dissociation of CA from the viral core
appears to be a critical step in controlling nuclear import
[33,34].
Among the HIV-dependency factors involved in HIV-1
replication, TNPO3 was recently shown to be involved
in a nuclear import and/or preintegration step [35-40].
TNPO3 is a karyopherin from the importin-ß family that
mediates transport of serine/arginine rich (SR) proteins
into the nucleus in a phosphorylation-dependent man-
ner [41]. Using yeast two-hybrid screenings, we identified
TNPO3 as a binding partner of IN [36,42]. Although a dir-
ect interaction between HIV-1 IN and TNPO3 has been
clearly established [36,43,44], recent reports indicated that
HIV CA is one of the viral determinants important for
TNPO3 requirement [8,38-40,44,45].
Once inside the nucleus, IN catalyzes viral cDNA inte-
gration into the genome of the host cell [46,47]. HIV-1
integration occurs preferentially in transcription units
(TUs) of transcriptionally active genes whereas CpG
islands and promoter regions are disfavored. Import-
antly, the targeting of viral integration to specific regions
of the host chromosome is under the control of LEDGF/
p75 [48-50]. LEDGF/p75 is a key factor of HIV-1 inte-
gration that was identified as an IN interacting factor
[51-53]. LEDGF/p75 is a cellular chromatin-associated
protein presumably involved in transcriptional regula-
tion of cellular genes [54-56]. LEDGF/p75 is tightly asso-
ciated to chromatin, and the molecular basis of this
interaction involves its conserved PWWP and AT-hook
domains in the N-terminal region of the protein [57,58].
LEDGF/p75 plays an important role in lentiviral cDNA
integration, as demonstrated by mutagenesis [52,59-61],
over-expression of LEDGF/p75 IBD (Integrase Binding
Domain) [62,63] as well as RNAi and knock-out studies
[49,50,62-65]. Structural studies revealed the roles of
both the catalytic core domain dimeric interface and the
N-terminal domain of IN for high affinity binding to
IBD [60,66,67]. Albeit not strictly essential for replica-
tion, LEDGF/p75 tethers PIC-associated IN to chroma-
tin to presumably stimulate its enzymatic activity at the
site of integration [57,58].
In this study, we explored at early times post infection
the dynamics of interaction between IN and its cellular
and viral partners. However, the detection of IN in
infected cells remains technically challenging. We took
advantage of a previously characterized virus carrying an
active tagged-IN with the HA epitope at the C-terminus
[68] to purify and characterize IN complexes in the con-
text of infected lymphocytes. Our results shed light on
the stability and distribution of IN during early steps of
HIV-1 infection. We show that IN is rapidly degraded in
a proteasome-dependent manner upon virus entry into
the cell. Immunoprecipitation experiments allowed us to
detect interactions between IN and its cofactors LEDGF/
p75 and TNPO3 at 6 h post-infection (p.i.). Using size
exclusion chromatography, we uncover that IN exists in
at least two distinct complexes in infected cells: a high
molecular weight complex that co-fractionates with viral
cDNA and integration activity, and a low molecular
weight complex devoid of viral cDNA that is found ex-
clusively in the nucleus and depends on LEDGF/p75
expression.
Results
HIV-1 integrase is rapidly degraded in a proteasome-
dependent manner upon cell infection
To facilitate HIV-1 integrase detection during the course
of cell infection, we took advantage of an infectious
HIV-1 viral clone carrying IN tagged at the C-terminus
with the HA epitope (HIV-1IN-HA [68]). Epitope fusion
at the C-terminus of IN disrupted the Vif open reading
frame. However, viral replication is Vif-independent in
SupT1 human lymphocytic cells used in our study [69].
Using this virus, we first analyzed IN stability during the
early steps of HIV-1 replication. Indeed, the ubiquitin
degradation pathway targets IN to the proteasome [70],
which may account for its short half-life in transiently
transfected cells [70,71]. SupT1 cells were exposed to
HIV-1 for 2 h and harvested at 2 h, 4 h and 6 h p.i. At
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each time whole cell extracts (WCE) were prepared and
viral proteins CA, MA and IN-HA were detected by
Western blotting. By optimizing cell infection conditions
in order to maximize cell-virus contact surface, incom-
ing CA, MA and IN-HA were readily detectable in cell
extracts of infected cells. Infection of cells with a heat
inactivated virus prevented detection of viral proteins in
cells extracts, indicating that we specifically detected
intracellular-associated viral proteins rather than virus
absorbed at the cell surface (Figure 1A). Strikingly, the
amount of IN-HA dramatically decreased during the 6 h
period of time, whereas amounts of CA remained stable
(Figure 1A and 1B). To ensure that the HA-tag did not
interfere with IN properties, we compared the stability
of HA-tagged and non-tagged IN proteins. SupT1 cells
were infected either with wild type HIV-1 or HIV-1IN-HA,
and IN was detected in cell lysates at different times post-
infection using an anti-IN antibody. Regardless of the
presence of a C-terminus HA-tag fusion, IN levels in cell
lysates rapidly decreased to become barely detectable at
6 h p.i. (Figure 1B). In addition, levels of late reverse tran-
scription product (LRT), 2-LTR circles and integrated viral
DNA were similar at 6 h p.i. for both viruses indicating
that the HA tag does not interfere with IN functions
during early steps of virus replication (data not shown).
Treatment of cells with proteasome inhibitor MG-132
resulted in rapid stabilization of IN-HA in infected
cells indicating that once IN entered in the cell, a sub-
set of the protein is actively degraded in a proteasome-
dependent manner (Figure 1C). We further analyzed
early steps of viral replication of HIV-1IN-HA. Quantitative
PCR analysis indicated that the maximum amount of
integrated provirus was reached at 10 h p.i (Figure 1D).
Taken together, our results showed rapid degradation of
IN protein upon cell infection, coinciding with detection
of integrated proviral forms at 6 h p.i. Therefore, we
decided to focus our study on early time points (i.e. 2 h p.i.
and 6 h p.i.) to monitor the dynamic of IN-containing
complexes.
Dynamic distribution of HIV-1 integrase complexes during
infection
The temporal dynamic of IN interactions with cellular
cofactors during early steps of HIV replication was char-
acterized by co-immunoprecipitation experiments. Inter-
actions between IN-HA and host partners TNPO3 and
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Figure 1 IN is rapidly degraded in a proteasome-dependent manner during early steps of HIV-1 replication. (A) SupT1 cells were
infected with HIV-1IN-HA or heat-inactivated virus (56°C). At indicated time post infection, cells were lysed and equivalent amounts of each sample
(100 μg of protein) were analyzed using Western blotting with antibodies against HA, CA, LEDGF/p75 and α-tubulin as loading control. (B) Both
IN-HA and non-tagged IN are rapidly degraded following viral entry into the cell. SupT1 cells were infected with HIV-1IN-HA or HIV-1wt. At
indicated time post infection, cells were lysed and equivalent amounts of each sample (100 μg of protein) were analyzed using Western blotting
with antibodies against IN and MA. Input represents 0.1% of the amount of virus used to infect the cells. (C) IN is targeted to proteasomal
degradation following infection of the cells. SupT1 cells were infected with HIV-1IN-HA in absence or presence of proteasome inhibitor MG-132. As
in (B), cell lysates were analyzed by Western blotting with antibodies against HA, β-Catenin and CA. β-Catenin was used as a control to monitor
the efficiency of MG-132 treatment. (D) Proviral integrated DNA is readily detected at 6 h p.i. SupT1 cells were infected with HIV-1IN-HA, and DNA
was extracted at indicated time post infection. Late reverse transcription product (LRT), 2-LTR circles and integrated viral DNA were quantified by
real time PCR.
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LEDGF/p75 were readily detected at 6 h p.i. (Figure 2).
To further assess the rapid changes of IN-associated
complexes during the early stages of HIV-1 replication,
we performed biochemical fractionation of infected cell
lysates. First, fractions from size-exclusion chromatog-
raphy of WCE were analyzed by Western blotting
against TNPO3 and LEDGF/p75. In non-infected cells,
the relatively broad elution profile of TNPO3 might
reflect its interactions with several different proteins/
cargos (fractions 17 to 33, Figure 3A). In contrast,
a major peak around 300 KDa (Fractions 2228,
Figure 3A) was observed for LEDGF/p75. In addition, a
small portion of LEDGF/p75 was found in higher mo-
lecular weight fractions (fractions 1719, Figure 3A).
Similar profiles were observed in infected cells (data
not shown), indicating that HIV-1 infection does not
trigger major changes in the distribution of LEDGF/p75
or TNPO3-associated complexes.
We then addressed the distribution of viral proteins
early following infection. At 2 h p.i., IN-HA was
detected in 2 complexes of different size and compos-
ition (Figure 3B). The high molecular weight complex
(IN complex I), which was excluded from gel separation
range (>1.3 MDa), was the most abundant one (fractions
1518, Figure 3B). Viral proteins capsid (CA) and matrix
(MA) were mostly found as free molecules (fractions
3644, Figure 3B and C), except for a small proportion
co-eluting with IN complex I (fractions 1517 for CA
and fraction 1720 for MA, Figure 3B).
Although present in a minor proportion, low molecular
weight (IN complex II) IN-HA complex peaked in frac-
tions 2325 (around 440 KDa). At 6 h p.i., IN-HA was still
found in IN complex I, but shifted readily to IN complex
II, while both CA and MA were only detected in smaller
peaks (fraction 3644) (Figure 3C). Noteworthy, IN-HA
detection required longer exposure times at 6 h than at
2 h p.i., due to its rapid degradation upon cell infection.
Together, our results indicate that shortly after infection,
IN associates with at least two distinct complexes.
IN low molecular weight complexes are devoid of viral
DNA and in vitro PIC activity
To detect viral DNA potentially associated with IN com-
plexes at these time points, we performed real-time PCR
on DNA extracted from fractionated WCE (Figure 3D).
At 2 h and 6 h p.i., viral DNA was detected in fractions
13 to 19 containing the IN complex I (Figure 3D). Elu-
tion of the viral cDNA in the void volume of the column
(>1.3 MDa) is consistent with its estimated molecular
weight (~6.4 MDa for the 9.7 kbp genome). In vitro inte-
gration activities of IN-containing complexes eluted
from the column were also measured at 6 h p.i.. To en-
sure optimal infection conditions, SupT1 cells were
infected with VSV-G pseudotyped HIV-1IN-HA and the
ability of viral DNA to integrate into target plasmid
in vitro was quantified by real-time PCR. Concomitant
with the detection of viral DNA and IN in fractions con-
taining complex I (Figure 4A and 4B), maximal PIC ac-
tivity was also reached in these fractions (Figure 4C).
Thereby, these data suggest that between 2 h and 6 h p.i.
a significant portion of IN accumulates in a low molecu-
lar weight complex devoid of viral DNA.
Accumulation of IN complex II does not require reverse
transcription nor integration but depends on LEDGF/p75
expression
To assess the role of reverse transcription in the accu-
mulation of IN complex II, fractionation of infected cell
IN-HA
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LEDGF/p75
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NI I
Input
NI I
IP-HA
IN-HA
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LEDGF/p75
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Figure 2 IN interacts with cellular cofactors LEDGF/p75 and
TNPO3 at 6 h p.i. SupT1 cells were not infected (NI) or infected (I)
with HIV-1IN-HA. WCE were prepared at 2 h and 6 h p.i. (as indicated),
immunoprecipitated (IP-HA) with the anti-HA affinity matrix and
analyzed by Western blotting using antibodies against HA, LEDGF/
p75, and TNPO3. Inputs represent 5% of the immunoprecipitated
material. To detect IN-HA at 2h p.i. the film was exposed for 5
minutes whereas detection of IN-HA at 6h p.i. required film exposure
of 30 minutes. Dividing lines indicate the grouping of parts of the
same gel.
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extracts were conducted in the presence or absence of
the non-nucleoside reverse transcriptase inhibitor Nevir-
apine. Nevirapine treatment did not affect the kinetics of
IN degradation (Figure 5A). Furthermore, upon reverse
transcription inhibition, IN was still detected in complex
II (Figure 5B and 5C), suggesting that the accumulation
of IN in low molecular weight complexes does not re-
quire the maturation of the reverse transcription com-
plex (RTC) into a PIC.
Next, we tested whether IN complex II could be the
result of a post-integration event leading to the release
of DNA-free IN from integrated intasomes. SupT1 cells
were infected with a virus harboring a catalytically
inactivated IND116A. At 2 h p.i., cell extracts were frac-
tionated by size exclusion chromatography and collected
fractions were analyzed by Western blotting. IN from
HIV-1IN D116A-HA eluted in two separate complexes
(I and II) that were indistinguishable from the complexes
In
pu
t
2415 2322212019 25 29 30 31 32 33 34 35 3616 17 18 37 38 39 40 41 42 43 44 45 46
669kDaVoid volume 443kDa
26 27 28
200kDa 150kDa 66kDa 29kDa
LEDGF
/p75
TNPO3
MA
IN-HA
CA
In
pu
t
2415 2322212019 25 29 30 31 32 33 34 35 3616 17 18 37 38 39 40 41 42 43 44 45 4626 27 28
A
B
C
D
IN-HA
In
pu
t
2415 2322212019 25 29 30 31 32 33 34 35 3616 17 18 37 38 39 40 41 42 43 44 45 4626 27 28
MA
CA
I II
 L
R
T
 c
o
p
ie
s
5000
10000
15000
20000
25000
15 17 19 21 23 37 39 41 4325 27 29 31 33 35
In
pu
t
2h p.i.
6h p.i.
16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
0
n.i.
2 h p.i.
6 h p.i.
I II
Figure 3 Two distinct IN complexes are detected following cell infection. SupT1 cells were either not infected (A) or infected with HIV-1IN-
HA, and WCE were prepared at 2 h (B) and 6 h p.i. (C). WCE were subjected to gel filtration on a Superdex 200HR 10/300 column. Fractions were
collected and analyzed by Western blotting using antibodies against LEDGF/p75, TNPO3, HA, MA, and CA. Inputs represent 3.5% of WCE load.
Two complexes containing IN were detected, a high molecular weight complex (IN complex I, >1.3 MDa), and a low molecular weight complex
(IN complex II, ~440KDa). To detect IN-HA at 2h p.i. in (B), the film was exposed for 5 minutes, whereas detection of IN-HA at 6h p.i. in (C)
required film exposure of 30 minutes. (D) Viral DNA co-elutes with IN complex I. Same as (A) and (B) except DNA was extracted from each
fraction and late reverse transcription product (LRT) content was quantified by real time PCR. Non-infected (NI) samples were used as controls
(not shown). Results shown are representative of two independent experiments. Dividing lines indicate the grouping of parts of the different gels
with identical times of film exposure.
Gérard et al. Retrovirology 2013, 10:13 Page 5 of 14
http://www.retrovirology.com/content/10/1/13
obtained with WT IN (Figure 6), indicating that accumula-
tion of IN complex II is not a post-integration event.
We then investigated whether the distribution of the
fractions containing IN was dependent on LEDGF/p75
expression. A LEDGF/p75-knock-down SupT1 cell clone
(TL34) and its control polyclonal cell line counterpart
(TC3) [72] were infected with VSV-G pseudotyped HIV-
1Δenv-Luc. As expected, knock-down of endogenous
LEDGF/p75 yielded a 10-fold decrease of viral infectiv-
ity, quantified by the viral encoded luciferase activity
(Figure 7A). Then, WCE from TC3 or TL34 cells
infected with HIV-1IN-HA virus for 2 h were fractionated
by size exclusion chromatography and collected fractions
were analyzed by Western blotting. Consistently, we
observed similar IN complexes (I and II) in TC3 lysates
as in wild type SupT1 lysates (compare Figure 7B with
3B). In sharp contrast, in TL34 cells knocked down for
LEDGF/p75 we observed a shift of IN complex II to-
wards a lower molecular weight complex (IN complex
III) with a molecular mass around 150 KDa (fractions
2731) (Figure 7C). Regarding the ability of IN to form
stable tetramers when expressed in human cells [51], we
decided to further characterize IN complex III. We thus
pooled fractions 3032 and performed proteins cross-
linking with increasing amount of the cross-linker ethyl-
ene glycol bis-succinimidylsuccinate (EGS). Addition of
0.25 to 2 mM of EGS yielded cross-linked complexes of
60, 90 and 130 KDa, with a strong predominance of the
latter band at the higher concentrations of cross-linker
agent (Figure 7D). Thus, depletion of LEDGF/p75 led to
the accumulation of IN complex III that contains tetra-
mers of IN.
IN complexes II and III are exclusively nuclear
We analyzed the cellular localization of the IN com-
plexes at 2 h p.i.. Cytosolic (CE) and nuclear extracts
(NE) prepared from infected control (TC3) or LEDGF/
p75-knock-down SupT1 cells (TL34) were fractionated.
LEDGF/p75 was only detected in nuclear fractions of
control cells, indicative of absence of NE contamination
of the CE (Figure 8A). In both TC3 and TL34 cells, IN
complex I was distributed between cytosolic and nuclear
fractions, indicating that PICs reached the nuclear com-
partment as early as 2 h p.i. (Figure 8A and 8B). In sharp
contrast, IN complex II was strictly associated with nu-
clear fractions and could not be detected in cytosolic
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Figure 4 Retroviral DNA and integration activity co-eluted with IN complex I. SupT1 cells were infected with HIV-1IN-HA pseudotyped with
VSV-G to increase infectivity. WCE were prepared at 6 h p.i. and subjected to gel filtration. (A) Fractions were collected and analyzed by Western
blotting using antibody against HA. (B) DNA was extracted from each fraction and late reverse transcription product (LRT) content was quantified
by real time PCR. (C) In vitro PIC activity was assayed for each fraction (see Methods for details).
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extracts of TC3 cells (Figure 8A). Concordantly, in ab-
sence of LEDGF/p75, IN complex III was also only
detected in nuclear fractions (Figure 8B). Taken together,
our data indicate that IN complex II associates with nu-
clear fractions in a LEDGF/p75-dependent manner.
A class II IN mutant virus failed to accumulate in low
molecular weight complexes
To further explore the mechanisms of the accumulation
of IN in low molecular weight complexes, we took
advantage of an IN class II mutant virus HIV-1IN Q168A-
HA that was first identified to be defective for LEDGF/
p75 interaction [52]. Mutation of the Q168 residue of IN
impairs its ability to form tetramers, resulting in a de-
crease of its concerted integration activity [43,73]. First,
the stability of the mutant IN Q168A was assessed during
infection. WCE from SupT1 cells infected with HIV-1IN
Q168A-HA were harvested at 2 h, 4 h, 6 h and 8 h p.i. and
viral proteins MA and IN were detected by Western
blotting. INQ168A levels decreased rapidly during the
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Figure 5 Inhibition of reverse transcription does not affect the accumulation of IN complex II. (A) IN is rapidly degraded in presence of
Nevirapine. SupT1 cells were infected with HIV-1IN-HA in absence or presence of 1 μM of Nevirapine. At indicated time post infection, cells were
lysed and analyzed using Western blotting with antibodies against HA and CA. The inhibition of reverse transcription was monitored in cell
extracts by the quantification of late reverse transcription products (LRT) by real time PCR. (B) and (C) SupT1 cells were infected with HIV-1IN-HA in
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and analyzed by Western blotting using antibody against HA (C).
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early phase of HIV-1 infection suggesting that, similar to
the WT IN, this mutant was degraded by the prote-
asome (Figure 9A). Next, the interaction between IN
and LEDGF/p75 was assessed in cells infected with HIV-
1 encoding wild type IN devoid of the HA tag, IN-HA
or INQ168A-HA. As expected, the Q168A mutation
ablated the LEDGF/p75-IN interaction (Figure 9B). Sur-
prisingly, fractionation of infected WCE indicated that
INQ168A failed to accumulate in low molecular weight com-
plexes at 2 h and 6 h p.i. (Figure 9C). However, the high
molecular weight complexes eluting in the void volume of
the column (IN complex I) is still associated both with the
cytoplasm and the nuclear fractions of the cells (Figure 9D).
Taken together, these results indicated that the nuclear
accumulation of IN complex II is impaired for a mutant
defective for LEDGF/p75 interaction and tetramerization.
Discussion
Studies of retroviral pre-integration complexes have
been hampered by the limited amounts available from
infected cells. In this study, we took advantage of an in-
fectious HIV-1 viral clone carrying a C-terminus HA-
tagged IN protein to explore IN low molecular weight
complexes shortly after cell entry.
Our results show that IN undergoes rapid degradation
by the proteasome shortly after its entry in the cyto-
plasm, whereas CA and MA remained stable. Previous
published data showed that HIV-1 IN over-expressed in
cells is actively degraded by the ubiquitin/proteasome
system in both N-end rule dependent and independent
pathways [52,70,71,74-76]. Furthermore, the binding to
LEDGF/p75 was shown to stabilize IN by preventing its
degradation by the proteasome [52,75]. However, we
observed a similar decrease of levels of the WT IN and
the Q168A mutant impaired for LEDGF/p75 interaction.
This is likely to reflect that at early steps of infection the
vast majority of IN entering the cell cytoplasm is not yet
accessible for LEDGF/p75 binding.
In preliminary studies aiming at analyzing the impact
of HIV-1 infection on cellular cofactors complexes using
a Superdex 200 10/300 GL column, we noticed that IN
eluted in a low molecular weight complex that was dis-
tinct from the large IN-containing complex detected
within the void volume of the gel filtration column. This
large complex also co-eluted with viral DNA and inte-
gration activity, indicative of the presence of active PICs
in these fractions. This observation is consistent with
previous characterizations of retroviral nucleoprotein
complexes in infected cells using gel filtration chroma-
tography [2,6,21,25]. In contrast, the low molecular
weight complex containing IN was devoid of viral cDNA
and integrase activity. This complex was not observed in
previous studies of HIV-1 PIC composition using gel
filtration chromatography [21] or fractionation by sucrose
gradient [77]. However, this is not surprising as these
analyses were restricted to the cytoplasmic fraction of
infected cells, precluding the detection of complex II
that we found to be exclusively in the nuclear fraction.
IN complex II could be similar to the one that was previ-
ously isolated from the nucleus of cells stably expressing
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Figure 8 IN complex II and III are exclusively nuclear. Control SupT1 cells TC3 (A) and LEDGF/p75-knock-down SupT1 cells (TL34) (B) were
infected with HIV-1IN-HA. Cytosolic and nuclear extracts (CE and NE, respectively) were prepared at 2 h p.i. and subjected to gel filtration on a
Superdex 200HR 10/300 column. Fractions were collected and analyzed by Western blotting using antibodies against LEDGF/p75, or HA. Inputs
represent 3,5% of WCE load. LEDGF/p75 served as an internal control for the nuclear fraction in (A).
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IN. In this report, tetramers of INs associated with
LEDGF/p75 were found in a complex with an estimated
mass around 400 KDa [51]. Accordingly, we found that
depletion of LEDGF/p75 lead to a shift towards a lower
molecular weight complex (IN complex III) that peaks
at ~150 KDa and contains tetramers of IN.
Non-exclusive hypothesis could explain the presence
of IN in a low molecular weight complex distinct from
the PIC. First, IN complex II could be the result of PIC
destabilization. Indeed, the relative increase of the pro-
portion of IN complex II at 6 h p.i. could reflect a dy-
namic shift of IN from active PICs to lower molecular
weight complexes lacking full-length viral cDNA. Several
mechanisms could account for the escape of IN from ac-
tive PICs. Inefficient reverse transcription [78,79], or
degradation of incoming viral cDNA by cytosolic exonu-
cleases like TREX1 [80] could lead to the destabilization
of PICs and the release of free IN. However, we did not
observe a significant change in the distribution of IN
complexes I and II upon inhibition of reverse transcription
by the non-nucleoside reverse transcriptase inhibitor
Nevirapine, challenging the hypothesis that IN complex
II formation is the result of abortive reverse transcrip-
tion complexes. Moreover, a catalytic inactive mutant
IND116A accumulated in complex II suggesting that it is
not the result of a post-integration event. Further experi-
ments will be required to assess the potential role of cellular
exonucleases in the release of low molecular weight IN
complexes distinct from the PICs.
A second hypothesis posits that IN complex II might
originate from IN molecules that are not associated with
the PIC. IN is incorporated in virions as part of the Gag-
Pol polyprotein precursor, and it is generally admitted
that between 30 to 100 of IN molecules are packaged
per retroviral particle [81]. Although a precise quantifi-
cation of IN incorporated into HIV-1 particles is still
being awaited, it is likely that IN is present in large
excess. Indeed, the functional intasome is formed by
tetramer of IN tightly bound to the LTR ends of the
newly synthesized viral cDNA [82,83]. Thus, this appar-
ent excess of DNA-free IN could lead to the formation
of IN complex II. Future experiments will reveal whether
C
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IN low molecular weight complexes play an active role
during HIV-1 replication.
Conclusions
We show that, shortly after the virus enters the cell, a
significant portion of IN distinct from active PICs forms
a low molecular weight complex in the nucleus that is
dependent on LEDGF/p75.
Methods
Cells and viruses
293 T cells were grown in DMEM plus glutamine, anti-
biotics and 10% decomplemented-FCS (foetal calf
serum) (GibcoBRL, Invitrogen). SupT1, TC3 and TL34
cells were grown in RPMI 1640 plus glutamine, antibio-
tics and 10% decomplemented-FCS (foetal calf serum)
(GibcoBRL, Invitrogen). Virus stocks were generated by
transfecting 293 T cells with either wild type or IN-HA
tagged Lai molecular clone (HIV-1IN-HA [68]) using
Fugene 6 reagent (Roche). HIV-1IN Q168A-HA and HIV-
1IN D116A-HA were generated by site-directed mutagen-
esis using HIV-1IN-HA as a template. Mutations were
confirmed by sequencing and subcloned back into the
PflMI sites of the WT HIV-1IN-HA. HIV-1 Δenv Luc has
been previously described [84]. VSV-G pseudotyped
viruses were produced by co-transfecting HIV-1IN-HA or
HIV-1 Δenv Luc with plasmid pMD.G [85]. Twenty-four
hours post-transfection, cells were washed with PBS and
supernatants were collected at 48 h and 72 h post-trans-
fection. The supernatants were 0.45-μm-filtered and
ultracentrifuged at 150,000 g for 1 h 30 minutes at 4°C.
Virus pellets from 30 ml of supernatants were resus-
pended in 75 μl of PBS. An equal volume of RPMI 1640
medium (GIBCO, Invitrogen) supplemented with 10%
fetal calf serum and antibiotics was added, and virus
stocks were stored at −80°C. HIV-1 CAp24 antigen was
quantified by ELISA (Innotests HIV Antigen mAb, Inno-
genetics, France).
Cell infection and cell extract preparation
SupT1 cells (2 × 108) were infected with 200 μg of
CAp24 (corresponding to a multiplicity of infection-
MOI- of 5, as quantified by real time PCR) of HIV-1 or
HIV-1 IN-HA virus in a total volume of 500 μl for 2 h at
37°C. When indicated, 20 μM of MG-132 was added
along the course of infection. Two hours later, cells
were washed three times in 25 ml of PBS and resus-
pended in RPMI 1640 medium supplemented with 10%
fetal calf serum and antibiotics at a final concentration
of 1.5 × 106 cells/ml. At different time post infection
cells were harvested, washed twice with 25 ml of PBS
and lysed in 3 cell pellet volumes of lysis buffer
(20 mM TrisHCl pH 8.0, 0.3 M KCl, 5 mM MgCl2,
10% (v/v) glycerol, 0.1% tween 20, 1 mM PMSF and
protease inhibitor cocktail from Sigma). Cell lysis was
completed by two successive rounds of freeze-thaw,
then incubated for 30 min at 4°C on rotating wheel.
Two successive centrifugation steps at 16,000 g for
30 min at 4°C allowed complete removal of insoluble
materials. The collected supernatant corresponding to
soluble proteins within the cells was called whole cell
extracts (WCE). Cytosolic and nuclear extracts were
obtained by sequential cell fractionation. Cells were first
washed in buffer A (20 mM HEPES-KOH pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 1 mM PMSF and protease inhibitor
cocktail from Sigma) and lysed 5 min on ice in 2 cell pellet
volumes in buffer A and 0.1% (v/v) NP-40. After centrifu-
gation of the cell lysate at 10,000 g for 5 min, the super-
natant corresponding to the cytosolic extract (CE) was
collected and the pellet was resuspended in 3 volumes of
buffer B (20 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2,
0.5 M NaCl, 25% (v/v) glycerol, 1 mM PMSF and protease
inhibitor cocktail from Sigma). After 15 minutes incuba-
tion on ice, the nuclear extract (NE) was collected by cen-
trifugation for 15 minutes at 14,000 g. CE and NE were
stored at −80°C.
PIC activity assay
The assay is based on the quantification of integration
events of viral cDNA into a parental vector (pTZ-19R)
[8] with the following modifications. SupT1 cells were
infected for 2 h with a VSV-G pseudotyped HIV-1IN-HA
virus and WCE were prepared at 6 h p.i. as previously
described. WCE (3 mg) were injected into Superdex 200
10/300 GL gel filtration column. Each fraction was col-
lected and treated with RNase A (final concentration at
20 μg/ml) for 20 minutes at RT in a final volume of
250 μl. Integration reaction assay was performed at 37°C
for 45 minutes by mixing each fraction with 1 μg of tar-
get plasmid pTZ-19R in integrase reaction buffer (INRB:
20 mM HEPES-KOH pH 7.4, 150 mM KCl, 1 mM
MgCl2, 4% glycerol, and 1 mM DTT added just before
starting the reaction) in a final volume of 350 μl. For
each fraction, negative control was performed by omit-
ting the target plasmid in the integration reaction assay.
The reaction was stopped by adding 0.5% SDS, 8 mM
EDTA and 0.5 mg/ml proteinase K for 1 h at 56°C. DNA
was then extracted with phenol and phenol:chloroform:
isoamylalcohol 25:24:1, using glycogen as carrier, and
stored at −20°C. Integration events were quantified using
a two-step PCR reaction. In the first round PCR, inte-
grated HIV-1 sequences were amplified using the HIV-1
specific LM667 primer [78] together with primers anneal-
ing to opposite strand of pTZ-19R in tail-to-tail fashion.
TZ2414 primer sequence is 5- GTTGTTCCAGTTTG
GAACAAGAGTC-3. TZ2413 primer sequence is 5-
ACTCAACCCTATCTCGGTCTATTC-3. To evidence
background PCR signal, TZ2414 and TZ2413 primers
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were omitted from each integration reaction. We per-
formed the second nested-PCR steps using conditions
previously described [78]. Results shown are indicated as
relative units of specific signal (signal from PCR with tar-
get and with TZ2414/TZ2413 primers) minus unspecific
signal (signal from PCR without target or without
TZ2414/TZ2413 primers). The copy number of integrated
DNA was determined in reference to a standard curve
obtained by concomitant two steps amplification of serial
dilution of the standard pNLX-HIVLTR vector. This con-
struct was generated by amplifying the LTR region (n.t.
1702, numbering based on NL4.3 sequence) and cloning
into BamH1 and Pst1 restriction endonuclease sites of
pTZ-19R.
Quantification of viral cDNA by real-time PCR
Prior to infection, viral stocks were treated 1 h at 37°C
with 100 U per ml of DNAseI (Roche applied Science).
SupT1 cells (6x106) were infected with viral doses corre-
sponding to 6 μg of HIV-1IN-HA CAp24 antigen in 12-
wells plates. At 2 h p.i., cells were washed twice in PBS.
At 2 h, 4 h, 6 h, 8 h and 10 h p.i. cells were harvested,
washed twice in PBS and DNA was extracted using the
QIAamp Blood DNA Minikit (Qiagen). Quantifications
of viral DNA were performed by real-time PCR using
the LightCycler 480 system (Roche Applied Science).
Primers, probes and PCR run conditions were described
previously [84]. The copy numbers of HIV-1 late reverse
transcription product (LRT) and 2-LTR circles were
determined using standard curves obtained by amplifica-
tion of cloned DNA containing the matched sequences.
The copy number of integrated HIV-1 DNA was deter-
mined in reference to a standard curve generated by
concomitant two-stage PCR amplification of a serial di-
lution of the standard HeLa HIVR7-Neo cell DNA [78].
Copy numbers of each viral form were normalized with
the number of cells obtained by the quantification by
PCR of the β-globin gene according to the manufacturer
instructions (Roche Applied Science).
Immunoprecipitation
For co-immunoprecipitation experiments, 3 mg of WCE
were mixed with 50 μl (50% slurry) of anti-HA affinity
matrix (clone 3 F10, Roche Applied Science) supplemen-
ted with protease inhibitor cocktail and 1 mM PMSF for
3 h at 4°C on rotating wheel. Beads were washed three
times with 15 volumes PBS-0.1% tween 20 for 5 minutes
on a rotating wheel at 4°C. IN-HA complexes were
directly resuspended in 1× loading sample buffer and
boiled for 5 min.
Chromatography
Whole cell extracts were subjected to size exclusion
chromatography at 4°C using an AKTA purifier system
(GE Healthcare). Four mg of WCE were injected on a
Superdex 200 10/300 GL column and 400 μl fractions
were collected at a flow rate of 0.5 ml/min of WCE buf-
fer. Proteins were precipitated over-night at 4°C in 10%
trichloroacetic acid, washed twice in cold acetone and
analyzed by Western blotting. Protein standards (Sigma)
were fractionated under same conditions to estimate the
size of the eluted protein complexes. When required,
DNA was extracted from each fraction using the
QIAamp Blood DNA Minikit (Qiagen).
Cross-linking
Cross-linking reactions were performed on gel filtration
fractions collected in 20 mM HEPES-KOH pH 7.2,
0.3 M KCl, 5 mM MgCl2, 10% glycerol, 0.1% tween 20,
1 mM PMSF and protease inhibitor cocktail (Sigma).
Fractions 3032, corresponding to part of IN complex
III, were pooled and proteins were cross-linked with
0.25 mM to 2 mM of the cross-linker ethylene glycol
bis-succinimidylsuccinate (EGS, freshly prepared) for
30 minutes at room temperature. The reaction was
stopped by adding TrisHCl pH 7.5 at a final concentra-
tion of 50 mM for 15 minutes at room temperature.
SDS-Page and Western-blotting
Proteins were separated by 4-12% gradient SDS-PAGE
(Invitrogen), transferred onto nitrocellulose membranes,
and revealed by Western-blotting using the following
antibodies as indicated: anti-CAp24 (AIDS Research and
Reference Reagent Program), anti-IN (Santa Cruz), anti-
MA (Hybridolab), anti-HA-HRP (clone 3 F10, Roche
Applied Science), LEDGF/p75 (BD Bioscience), TNPO3
(Abcam), and α-tubulin (Sigma-Aldrich).
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